kabutan

Pharma Foods International Co., Ltd.(2929) Summary

2929
TSE Prime
Pharma Foods International Co., Ltd.
750
JPY
-1
(-0.13%)
Dec 5, 2:15 pm JST
4.84
USD
Dec 5, 12:15 am EST
Result
PTS
outside of trading hours
750.8
Dec 5, 2:10 pm JST
Summary Chart Historical News Financial Result
PER
21.6
PBR
1.88
Yield
3.33%
Margin Trading Ratio
2.27
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
748 JPY 4.82 USD
Previous Close Dec 4
751 JPY 4.83 USD
High Dec 5, 9:27 am
764 JPY 4.92 USD
Low Dec 5, 9:00 am
747 JPY 4.81 USD
Volume
123,700
Trading Value
0.09B JPY 0.60M USD
VWAP
754.15 JPY 4.87 USD
Minimum Trading Value
75,000 JPY 484 USD
Market Cap
0.02T JPY 0.14B USD
Number of Trades
276
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
434
1-Year High Sep 11, 2025
4,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 123,100 753,600 6.12
Nov 21, 2025 122,700 727,100 5.93
Nov 14, 2025 132,000 734,700 5.57
Nov 7, 2025 128,800 834,000 6.48
Oct 31, 2025 162,000 788,300 4.87
Company Profile
Pharma Foods International Co., Ltd. primarily sells functional food ingredients such as GABA and folic acid egg supplements. The company is also involved in the development of antibody-based pharmaceuticals.
Sector
Foods
Pharma Foods International Co., Ltd. engages in the research, development, and manufacturing of functional ingredients, health foods, and pharmaceuticals. The company operates a B2B business, supplying materials to food and pharmaceutical manufacturers as well as distributors. They offer ingredients such as Pharma GABA, which provides stress relief and blood pressure improvement functions. Additionally, the company develops and sells its own brand products both domestically and internationally. In their B2C business, Pharma Foods International directly sells supplements, quasi-drugs, and cosmetics containing their proprietary functional ingredients to consumers through mail order. The Biomedical division conducts drug discovery research and development targeting intractable diseases such as autoimmune disorders and fibrosis, while also providing contracted services like proteome analysis. Furthermore, the company has expanded into venture capital and investment businesses.